TerminatedPhase 3NCT01012297
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Studying Leiomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Martee Hensley, MDNRG Oncology
- Intervention
- Bevacizumab(biological)
- Enrollment
- 107 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2009 – 2015
Study locations (30)
- Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- John Muir Medical Center-Concord Campus, Concord, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Los Angeles County-USC Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- University of California San Diego, San Diego, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- Olive View-University of California Los Angeles Medical Center, Sylmar, California, United States
- John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States
- The Medical Center of Aurora, Aurora, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01012297 on ClinicalTrials.govOther trials for Leiomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07125183Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic LeiomyosarcomaUniversity of Colorado, Denver
- ENROLLING BY INVITATIONNANCT07405346A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized EfficacyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT06957431Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaWashington University School of Medicine
- RECRUITINGPHASE2NCT07076186Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMSM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT06528769Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaGabriel Tinoco
- RECRUITINGPHASE2NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the TumourUNICANCER
- RECRUITINGPHASE2NCT06571734XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable LeiomyosarcomaNorthwestern University
- RECRUITINGPHASE1NCT06308419A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or DeletionsM.D. Anderson Cancer Center